Compugen Q1 2026 Deep Dive: EPS Misses by 14.3%, Revenue Down 5% – Alphastreet

AlphaStreet Newsdesk powered by AlphaStreet Intelligence

Compugen Ltd. (CGEN) missed Q1 2026 earnings expectations, reporting a lack of $0.08 per share in opposition to the consensus estimate of a $0.07 loss, marking a 14.3% miss that despatched shares down 9.2%. The biotechnology firm’s income of $2.2 million declined 4.7% 12 months-over-12 months, persevering with a sample of anemic high-line efficiency that has plagued the medical-stage firm all through 2025. The miss extends Compugen’s current observe file of failing to satisfy Wall Avenue’s benchmarks, with zero beats in its final quarter reported.

The earnings high quality image reveals a deteriorating value construction overwhelming minimal income era. Internet margin compressed dramatically to detrimental 350.0% in comparison with detrimental 313.0% within the 12 months-in the past quarter, representing a 37 share level deterioration. Working margin deteriorated much more severely to detrimental 409.9%, suggesting the corporate’s analysis and improvement spending is accelerating whereas income stays flat. Administration acknowledged this dynamic, noting that “R and D bills for the primary quarter of 2026 have been roughly $6.9 million in comparison with roughly $5.8 billion within the first quarter of 2025.” The online loss widened to $7.7 million from $7.2 million 12 months-over-12 months, whereas gross margin of 16.0% on gross revenue of simply $352,000 signifies the corporate generates minimal contribution from its collaboration and licensing income to offset its substantial working bills.

The loss per share remaining flat at $0.08 12 months-over-12 months masks underlying deterioration within the enterprise mannequin. Whereas the headline EPS determine suggests stability, the widening internet loss from $7.2 million to $7.7 million signifies the corporate required extra share dilution or a bigger share base to keep up the identical per-share loss determine. This dynamic is especially regarding for a medical-stage biotechnology firm that requires steady capital infusion to fund trials. The working loss expanded alongside rising R&D spending, suggesting Compugen is in an funding section for its pipeline with out corresponding income progress to partially offset these bills.

Price administration confirmed modest self-discipline typically and administrative capabilities. Administration famous that “our GNA bills for the primary quarter of 2026 have been roughly $2.3 million in comparison with roughly $2.4 million for the comparable interval in 2025,” representing a slight discount. Nonetheless, this $100,000 financial savings pales in opposition to the rising R&D expenditures and offers inadequate offset to forestall margin compression. For an organization at Compugen’s stage with minimal income, the burden of proof lies in demonstrating medical progress that justifies the money burn fee somewhat than incremental G&A effectivity.

Scientific trial progress stays the central worth driver, with administration sustaining timeline steering regardless of declining to replace enrollment metrics. When pressed on trial enrollment, administration acknowledged “we’re not commenting at this cut-off date, however I’ll say to you that we’re on observe for our interim evaluation as deliberate within the first quarter of 2027.” This non-disclosure on enrollment specifics whereas reaffirming the Q1 2027 interim evaluation timeline suggests both confidence in assembly milestones or strategic ambiguity to handle investor expectations. The interim evaluation represents the essential close to-time period catalyst that may decide whether or not Compugen’s present money burn fee interprets into worth creation or additional dilution.

The 9.2% inventory decline to $2.75 displays investor frustration with the earnings miss and absence of tangible progress markers. For a medical-stage biotechnology firm buying and selling at this worth degree, the market is signaling skepticism about both the likelihood of medical success or the corporate’s capability to achieve knowledge readouts with out important extra dilution. The This fall 2025 income spike that generated a revenue of $0.60 per share and $56.8 million in internet revenue now seems to be a non-recurring occasion, resetting investor expectations again to a loss-making profile till significant medical catalysts materialize.

This content material is for informational functions solely and shouldn’t be thought-about funding recommendation. AlphaStreet Intelligence analyzes monetary knowledge utilizing AI to ship quick and correct market info. Human editors confirm content material.